Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision To Bring “Off-The-Shelf” NK Cell-Based Cancer Treatments Rapidly To Patients

Excerpt from the Press Release:

SAN DIEGO and STOCKHOLM, June 4^th, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, Karolinska Institutet (“KI”) in Stockholm, Sweden, aimed at producing novel cell-based therapeutics using natural killer (“NK”) cells derived from induced pluripotent stem cells (“iPSCs”). Sorrento and KI are collaborative partners in the Competence Center for the development of next-generation NK cell-based cancer immunotherapies (“NextGenNK”) coordinated by KI.

Under the agreement, Sorrento will provide know-how in the core chimeric antigen receptor (“CAR”) and dimeric antigen receptor (“DAR”) technologies and support the collaborative effort to develop new CAR-NK and DAR-NK candidates, as well as fund the translational validation of the technologies. Multiple product candidates will be developed and tested in the initial phase of the planned work, with the goal that the candidate products will qualify for further human clinical trials.

The foundational Sorrento research assets critical to this program are novel proprietary CAR and DAR constructs identified through Sorrento’s proprietary G-MAB™ fully human antibody library and previously validated as determinants of cell-based therapy potency against hematologic and solid tumors.

Click the button below to read the entire Press Release:

Continue Reading The Press Release